GRFS:NASDAQ
Grifols SA - ADR ADR Class B
$7.40
arrow_upward
+0.54%(+0.040) 1D
$7.40
0.00% (0.00)
bedtimeAfter hours
Closed: Sep 16, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GRFS...
Open
$7.41
High
$7.41
Low
$7.34
Mkt. cap
6.74B
Avg. vol.
391.44K
Volume
0.00
Dividend
1.27%
Quarterly dividend
$0.02
Ex-dividend date
Jun 30, 2026
P/E ratio
9.64
52-wk high
$10.23
52-wk low
$6.96
EPS
$0.77
Beta
0.67
Shares outstanding
261.42M
No. of employees
25K
Open
$7.41
High
$7.41
Low
$7.34
Mkt. cap
6.74B
Avg. vol.
391.44K
Volume
0.00
Dividend
1.27%
Quarterly dividend
$0.02
Ex-dividend date
Jun 30, 2026
P/E ratio
9.64
52-wk high
$10.23
52-wk low
$6.96
EPS
$0.77
Beta
0.67
Shares outstanding
261.42M
No. of employees
25K
News stories
From web sources and news partners
Seeking Alpha
·
3 hours ago
Grifols Stock: Better Plasma Economics Can Unlock A Discounted Equity (NASDAQ:GRFS)
Profile
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over 30.
Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
About Grifols SA - ADR ADR Class B